Today: 8 February 2026
Subscribe
Browse Category

Healthcare News News 9 December 2025 - 6 February 2026

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares rose 2.7% to $27.22 Friday after the FDA granted Priority Review to its hemophilia drug HYMPAVZI, with a decision expected by mid-2026. Trading volume reached 30 million shares. The company also launched the TrumpRx discount program, offering cash discounts on over 30 drugs. The White House said TrumpRx.gov debuted Thursday with “most-favored nation” pricing on 40 branded drugs.
6 February 2026
···
Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer stock drops as Medicare puts Xeljanz on 2028 price-talk list, earnings next week

Pfizer shares fell 1.8% to $26.02 after U.S. Medicare included Xeljanz in its upcoming drug price negotiations, set to begin in 2026 with prices effective in 2028. The Centers for Medicare & Medicaid Services named 15 drugs for talks, and companies must decide by February 28 whether to participate. Investors are awaiting Pfizer’s February 3 earnings for updates on pricing risks.
28 January 2026
······
Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK share price in focus after China clears Trelegy for asthma — what to watch next week

GSK shares closed down 0.2% at 1,801 pence in London Friday after China approved Trelegy Ellipta for uncontrolled asthma in adults. The expanded label gives GSK access to an estimated 46 million adults with asthma in China. Investors await GSK’s Q4 and full-year results, set for Feb. 4. The FTSE 100 slipped 0.07% on the day.
24 January 2026
·····
ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio stock set for volatile week after ANKTIVA sales jump and new trial update

ImmunityBio shares surged 39.8% Friday after reporting a 750% jump in 2025 ANKTIVA sales and new regulatory approvals, including in Saudi Arabia. The company said its pivotal bladder cancer trial is over 85% enrolled, with completion targeted for Q2 2026. ImmunityBio ended the quarter with $242.8 million in cash. Investors await audited 2025 results and further updates on ANKTIVA and CAR-NK programs.
17 January 2026
···
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S. shares rose 1.4% in premarket trading after the company denied any relationship with SaveRxCanada.to, which claims to sell India-sourced Ozempic to U.S. patients at $280 per pen. Novo said it has not supplied Ozempic to the platform. The dispute comes as drug pricing faces renewed political scrutiny and ahead of the J.P. Morgan Healthcare Conference.
9 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharmaceuticals shares rose about 18% in premarket trading after the FDA approved its motion-sickness drug Nereus (tradipitant). The company plans to launch the oral treatment in the coming months. The approval followed late-stage trials involving 681 patients. Shares closed at $7.03 Tuesday and were indicated around $8.30 early Wednesday.
31 December 2025
···
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna shares rose about 9% to $33.80 after the company secured up to $54.3 million from CEPI for a Phase 3 trial of its H5 bird flu vaccine. The funding follows a canceled U.S. government contract earlier this year. Meanwhile, U.S. regulators are reviewing possible COVID-19 vaccine safety issues, with conflicting reports on potential FDA warnings.
20 December 2025
·
GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) announced today that the FDA approved Exdensur (depemokimab‑ulaa) for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc (LSE/NYSE: GSK) is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur (depemokimab‑ulaa)—a new twice‑yearly biologic for severe asthma—while also releasing its latest share buyback update through a regulatory filing. Investegate+1 Below is a full, reader-friendly rundown of all current GSK news items dated 17.12.2025, plus what they signal for patients, clinicians, and investors. Today’s GSK headlines (17.12.2025) 1)
17 December 2025
···
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and Company (NYSE: LLY)Stock price (last close):$1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but still powerful: blockbuster momentum in obesity/diabetes, fresh late-stage data that raises the bar for next-generation weight loss drugs, and a steady stream of regulatory and access headlines that keep Lilly’s pipeline and pricing strategy in the spotlight. This week’s narrative was dominated by three themes investors will keep debating into the week ahead: (1) how big retatrutide can become—and whether
13 December 2025
···
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1 By late afternoon, Immunovant stock was trading around $25.75, up roughly 9% on the day, with an intraday range between $22.03 and $25.87, giving the company a market value of about $4 billion.Stock Titan That upbeat finish came despite an initial sell‑off; one early report noted shares dropped around 7%
11 December 2025
····
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3 This is the kind of setup that gets both momentum traders and long‑term biotech nerds leaning in. Where KYMR Stock Stands Today The immediate driver: KT‑621, Kymera’s oral STAT6 degrader, produced dupilumab‑like efficacy in atopic dermatitis (eczema) with clean safety in a small Phase 1b trial — and the Street went into
9 December 2025
····
1 2

Stock Market Today

Cambricon Class A stock price dips again: what to watch next for China AI chip name 688256

Cambricon Class A stock price dips again: what to watch next for China AI chip name 688256

8 February 2026
Cambricon Technologies shares closed at 1,036.99 yuan in Shanghai on Friday, down 2.02%, with volume at about 8 million shares. The stock has fallen roughly 16.5% since Feb. 2 after sharp declines earlier in the week. Investors await the company’s next earnings report, due March 13, for confirmation of its forecasted profit turnaround. Cambricon is valued at about 437.28 billion yuan.
Infineon stock in focus after Friday rise as reports flag April price hikes for power chips

Infineon stock in focus after Friday rise as reports flag April price hikes for power chips

8 February 2026
Infineon shares closed up 1.5% at 42.04 euros Friday on Xetra after reports the company plans April price hikes on some power products. TrendForce said the increases, citing tight supply and higher costs, would apply from April 1. The Feb. 12 record date and Feb. 19 annual meeting are next for shareholders. UBS raised its price target to 47 euros, citing stronger margins.
TE Connectivity stock jumps 3.5% into the weekend — what to watch for TEL next week

TE Connectivity stock jumps 3.5% into the weekend — what to watch for TEL next week

8 February 2026
TE Connectivity (NYSE: TEL) closed Friday up 3.46% at $215.91, rebounding after a 3.29% drop Thursday, but remains 5% lower for the week and 14% below its 52-week high. The company expects to close a $750 million senior notes offering on Monday and pay a $0.71 dividend March 13. Investors await Friday’s U.S. CPI report, seen as a key market driver.
Go toTop